Revised SPCs: Humalog (insulin lispro) products
SPCs now advise patients must continuous rotate injection site to reduce risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions.
Source:
electronic Medicines compendium